Lin Elizabeth Yeu sold $771K of TARS

Lin Elizabeth Yeu (Chief Medical Officer) sold 9,988 shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $77.17 ($73.86–$80.00, $0.77M total) across 2 trades over 2026-09-01 to 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lin Elizabeth Yeu
Published Sep 3, 2026, 8:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TARS
Neutral
medium confidence
Mentioned
$TARS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSNeutralLow
01

Why it matters

The disclosed sale reduces insider ownership but does not indicate a material shift in control or strategy.

02

Market read

Primary insider sale filing; modest size, limited immediate trading impact.

03

What to watch

Potential upcoming clinical data releases or FDA decisions could outweigh the insider sale signal.

Relevance 4/10Novelty 5/10Timing: filing 2026-09-03

Background

Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$TARSNeutralMedium confidence
Context

Chief Medical Officer Lin Elizabeth Yeu sold 9,988 shares for $770.8K via a 10b5‑1 plan, reducing her stake to 13,320 shares.

Expected impact

Potential short‑term pressure on TARS, limited upside unless further news emerges.

Evidence & confidence

The sale is a routine 10b5‑1 execution; market reaction typically muted for sub‑$1M disposals.

Market effects

Minimal impact on biotech sector; insider sales are common and not sector‑wide drivers.

No significant regional effect; company is US‑listed.

Limited global relevance beyond TARS shareholders.

Counterpoint

The sale could be a liquidity move unrelated to company outlook; investors might view it as neutral.

Key entities

  • Lin Elizabeth Yeu

    Chief Medical Officer of Tarsus Pharmaceuticals.

  • Tarsus Pharmaceuticals, Inc.

    Biotech firm focused on rare disease therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TARSHighAI 8/10

Tarsus (TARS) Q3 2026 Earnings Call Transcript

Tarsus (TARS) reported Q3 2026 net product sales of $194.6M for XDEMVY, up 64% YoY. The company raised full-year sales guidance to $715M-$730M. Key growth drivers include increased patient demand, broader ECP prescribing, and retreatment. Tarsus also discussed pipeline progress and acquisition integration.

$TARSMedAI 8/10

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.